Webinar

Advancing Prostate Cancer Drug Discovery with Translational Preclinical Models

Tuesday, June 30, 2026 | 10:30 AM and 1:00 PM ET

Prostate cancer remains one of the most commonly diagnosed cancers in men and continues to present major challenges in oncology drug development, particularly in metastatic and treatment-resistant disease. As the therapeutic landscape rapidly evolves beyond standard androgen receptor pathway inhibition, translationally relevant preclinical models have become critical for understanding tumor biology, evaluating therapeutic response, identifying resistance mechanisms, and accelerating smarter drug development decisions.

In this webinar, Rajendra Kumari explores how clinically relevant in vitro and in vivo prostate cancer models are helping advance the next generation of therapies shaping the future of prostate cancer treatment. Rajendra highlights how diverse model systems and integrated translational approaches can support the development of innovative modalities including androgen receptor degraders, radioligand therapies, antibody-drug conjugates (ADCs), bispecific antibodies, immunotherapies, targeted therapies, and combination strategies designed to overcome resistance.

Register Now

In this webinar, we will:

• Explore the role of translational preclinical models in advancing prostate cancer drug discovery
  
  
• Discover how advanced preclinical platforms can better capture the complexity, heterogeneity, and evolving biology of prostate cancer to improve confidence in candidate selection and translational success
  
  
• Understand how the right models support the evaluation of emerging therapies, including:
  
  
  • Androgen receptor degraders and next-generation hormonal therapies
  • ADCs and radioligand therapies
  • Bispecific antibodies and T-cell engagers
  • Combination treatment strategies designed to overcome resistance
    
    
• Identify approaches for studying disease progression, metastasis, and treatment resistance
  
  
• Gain insights into translational strategies for evaluating efficacy, biomarkers, and mechanism of action, with practical considerations for designing robust prostate cancer preclinical studies
  
  
• Improve decision-making and confidence in go/no-go candidate selection during preclinical development

Register Now

About The Presenters:

Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience

As Executive Director of Integrated Solutions, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held an Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities. Rajendra co-founded PRECOS Ltd., serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with R&D, multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.